Health House International has begun a non-interventional observational study in Germany examining the effect of its cannabis extracts on quality of life of patients and their safety and tolerability.
Launched by CanPharma and supported by Kalapa Clinic, both 100% owned by Health House, the results from the 600-patient study will assist in improving the knowledge and confidence of medical professionals when prescribing cannabis extracts.
Health House CEO, David Attwood, commented: “As a leader in the field of medicinal cannabis, we recognise that due to the limited historical data currently available on the medical use of cannabis, practitioners face uncertainty when it comes to prescribing.
“Optimal patient care needs medical progress as well as professional education. In cooperation with leading experts, CanPharma is working to advance the clinical evidence for the use and effectiveness of cannabis-based medicines.”
The study will be using CanPharma’s full-spectrum cannabis extracts and will run for two years, with the first interim results expected in approximately six months.
The analysis of data sets collected from patients will support treatment safety as well as the ongoing improvement and standardisation of individualised cannabinoid therapy, and the individual observation period for each participant is six months.
Dr Henrik Sprengel, executive director of Health House and CEO of CanPharma, added: “Cannabis treatment must be tailored to the individual needs of patients. Gaining knowledge about the safety and tolerability of our cannabis extracts under everyday conditions is an important task that will drive confidence of medical professionals in prescribing.
“We are pleased and proud to be doing pioneering work here and to be driving the acquisition of scientific data.”
The observational study is being conducted by the first medical cannabis counselling centre to be established in Europe – the Kalapa Clinic – an independent part of the Health House group.
AMP exclusive enters cannabis extract distribution agreement in Germany
The three-year agreement will see AMP become the exclusive distribution partner for Australia-based Little Green Pharma.
AMP Alternative Medical Products (AMP) and Little Green Pharma (LGP) have entered into the partnership for the distribution of full-plant cannabis extract oils in Germany.
This will include LGP’s 20:5 LGP Classic and 10:10 LGP Classic extract oils in 30 and 50 milliliter sizes.
Managing director of Little Green Pharma, Fleta Solomon, commented: “We set the strategic objective to be one of the leading medical cannabis extract producers and distributors in Europe, which means being a leader in Germany, the largest medical cannabis market in the world.
“Our partnership with Greenrise Global’s daughter company, AMP Alternative Medical Products GmbH, puts us on course to that path.”
Dr Stefan Feuerstein, president and director of Greenrise Global and managing director of AMP, commented: ”We are seeing the industry mature with the growth of pharmaceutical cannabis products over flowers and are excited about adding LGP medical cannabis extracts to our portfolio.”
LGP was among the first medical cannabis companies to produce and export medical cannabis oils to Germany.
The company is also the primary medical cannabis extract oil supplier in France’s two-year medical cannabis trials being conducted by the French National Agency for the Safety of Medicines and Health Products.
AMP Alternative Medical Products begins Dronabinol sales in Germany
The company is a medical cannabis subsidiary of Greenrise Global Brands.
AMP Alternative Medical Products (AMP) and Eurox Pharma have begun the sales of Dronabinol produced in Germany by Eurox.
Greenrise Global subsidiary, AMP and Eurox, a SEED Innovations Limited portfolio company and one of Europe’s leading medical cannabis companies, entered into a non-exclusive marketing and distribution agreement for Dronabinol for sale in pharmacies to begin in February 2022.
In preparation for sales, AMP has trained its national sales team on the benefits of Dronabinol – a pure THC product primarily used in pain therapy – for patients to doctors and preparation methods for pharmacists.
Chairman of Eurox, Neil Smith, commented: “If you’re a believer in the ‘Made in Germany’, then that means Eurox.
“AMP’s focus on serving German patients and its national sales coverage make them a perfect partner for us.”
Eurox was one of the first medical cannabis companies to produce Dronabinol made in Germany at one of Europe’s largest GMP facilities located in Hessen, Germany.
The company controls the entire supply chain from cultivation, production to distribution ensuring a stable and efficient supply to its customers.
AMP is based in Erfurt and supplies medical cannabis products to pharmacies across Germany, including medical cannabis brands from Aphria, Bedrocan, Little Green Pharma and AMP’s branded line of products.
Eurox began the white label sale of its dronabinol products to a number of select customers in November 2021. Eurox selected Materia Deutschland, a wholly-owned subsidiary of European medical cannabis and CBD wellness products Materia, as as a distribution partner for its medical cannabis extracts.
Agreement aims to approve first cannabis vaporiser for European patients
A collaboration will see studies undertaken to prove the efficacy and safety of the device.
German-based Eurox Group has entered into an exclusive agreement with the US multi-state Orchid Ventures.
Under the agreement, Eurox, PurTec and JWEI, the company’s original equipment manufacturer (OEM) supplier and partner, will submit one of PurTec’s premium disposable vaporiser devices to authorities in Germany for Medical Device Approval.
The agreement is PurTec’s first European project.
Founder, CEO and chairman of Orchid, Corey Mangold, commented: “After months of planning and strategising, we are pleased to announce our partnership with such an established group in Eurox.
“We’re thrilled to join forces with Eurox and to be submitting one of our most stringently tested vaping products for Medical Device Approval with German health authorities.
“Once the product is accepted, this will be a huge step forward in our ability to deliver one of the first vaping products to patients and consumers in Germany along with several other European countries.
“We are confident that with the combined experience and expertise of Eurox and JWEI, we will succeed in getting approval and be among one of the first vaporiser products in-market and available to consumers throughout the EU.”
The companies will be working on several requirements and safety studies to prove the efficacy and safety of the device, and have already begun securing various certifications to speed up the approval process.
If and when approval is given for the device Eurox will have exclusivity regarding sales and distribution of the PurTec product in the European Union, United Kingdom and Brazil.
Co-CEO of Eurox, Dr Bernhard Babel, commented: “We are excited about this partnership.
“We believe that PurTec and JEWI will be valuable, long-term partners that can help us expand access to relevant and exciting new products that will compliment our portfolio and advance our growth trajectory.
“Our objective is to deliver with liquid vaping a controlled and consistent therapy form to patients with need for inhaling in Europe and beyond.”